Our mission is to provide hope to those who may have lost faith in finding solutions for complex, chronic diseases. We employ data to identify the underlying causes, develop an evidence-based, personalized combination therapy, and work collaboratively with patients, caregivers, and health care providers to improve outcomes.

With a team of doctors, scientists, technology experts, and seasoned entrepreneurs, Muses Labs is bringing to market a next-generation personalized combination therapy for Alzheimer’s disease.

The approach we’re employing relies upon advanced software and big-data analytics, and incorporates decades of medical research. Muses Labs offers a service that utilizes the Internet and information technology innovations to make the Protocol practical and accessible to individuals with cognitive decline around the world.

OUR TEAM

The company was co-founded by CEO, Vik Chandra, and CTO, John Q. Walker, PhD. Chandra has more than 26 years of technology leadership and development experience, including two decades with IBM. Walker is a computer software veteran and serial entrepreneur with nearly four decades at IBM and three start-ups under his belt. He led the team in the development of the groundbreaking algorithms while managing data in a high security, HIPAA-compliant environment.

Chandra and Walker’s technology expertise is complimented by a Scientific Advisory Board, which consists of several of the top leading experts in memory loss, as well as additional experts in technology, medical affairs, research, and patient care who help shape the direction of the company’s technology and scientific protocols.

MUSES LABS LEADERSHIP TEAM

Vik Chandra

Vik Chandra

Chief Executive Officer
John Q. Walker, Ph.D.

John Q. Walker, Ph.D.

Chief Technology Officer
Paul Reder, MS

Paul Reder, MS

Chief Architect
Dorothy Keine, MS

Dorothy Keine, MS

Medical Affairs Manager
Dan Hillmer

Dan Hillmer

Director Business Development

SCIENTIFIC ADVISORY BOARD

A Scientific Advisory Board, consisting of leading Alzheimer’s disease researchers and health care providers representing multiple institutions, shapes the direction of company’s technology and protocols.

Dr. Marwan Sabbagh, MD, FAAN

Dr. Marwan Sabbagh, MD, FAAN

Chief Medical-Scientific Advisor

Director, Alzheimer’s and Memory Disorders Division Barrow Neurological Institute, AZ

Dr. Mary Sano, PhD

Dr. Mary Sano, PhD

Advisor

Professor of Psychiatry, Associate Dean for Clinical Research, Mount Sinai School of Medicine, New York, NY

Dr. Ken R. Pelletier, MD, PhD

Dr. Ken R. Pelletier, MD, PhD

Advisor

Clinical Professor of Medicine, University of Arizona College of Medicine, Clinical Professor of Medicine, University of California School of Medicine, San Francisco (UCSF)

Dr. Kathleen Welsh-Bohmer, PhD

Dr. Kathleen Welsh-Bohmer, PhD

Advisor

Director, Bryan Alzheimer’s Disease Research Center, Professor, Duke University, Durham, NC

Dr. Mikhail Kogan, MD

Dr. Mikhail Kogan, MD

Advisor

Medical Director, Integrative Medicine Fellowship Director, Primary Care Internal Medicine, Geriatrics, Functional Medicine, George Washington Center for Integrative Medicine, Washington DC